Fennec Pharmaceuticals Inc.
FENC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001211583
In the last 90 days, Fennec Pharmaceuticals Inc. insiders filed 0 open-market purchases and 4 sales; 105 institutions reported holding it in 13F filings for Q2 2026, worth $175.1M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 13, 2026, 1:18 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $9.74M (21.8% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 24, 2026 | Mar 10, 2025 | Mar 25, 2024 | – | – |
| Revenue | $44.6M | $47.5M | $21.3M | – | – |
| Cost of revenue | – | – | $1.26M | $86.0K | – |
| Gross profit | – | – | $20.0M | $1.45M | – |
| Operating expenses | $50.9M | $45.0M | $32.8M | $24.0M | $17.2M |
| Research and development | $250.0K | $307.0K | $56.0K | $3.53M | $4.98M |
| Selling, general and administrative | $28.3M | $23.1M | $20.6M | $17.7M | $12.2M |
| Operating income | -$6.28M | $2.57M | -$12.8M | -$22.6M | -$17.2M |
| Interest expense | $2.08M | $4.07M | – | – | – |
| Income tax | $106.0K | $365.0K | – | $0 | $0 |
| Net income | -$9.74M | -$436.0K | -$16.0M | -$23.7M | -$17.3M |
| EPS, basic | $-0.34 | $-0.02 | $-0.60 | $-0.90 | $-0.67 |
| EPS, diluted | $-0.34 | $-0.02 | $-0.60 | $-0.90 | $-0.67 |
| Weighted shares, basic | 28.6M | 27.3M | 26.6M | 26.3M | 26.0K |
| Weighted shares, diluted | 28.6M | 27.3M | 26.6M | 26.3M | 26.0K |
| Margins and growth | |||||
| Gross margin | – | – | 94.1% | – | – |
| Operating margin | -14.1% | 5.4% | -60.1% | – | – |
| Net margin | -21.8% | -0.9% | -75.5% | – | – |
| Revenue growth, year over year | −6.1% | +123.7% | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 24, 2026 | Mar 10, 2025 | Mar 25, 2024 | – | – |
| Cash and equivalents | $36.8M | $26.6M | $13.3M | $23.8M | $21.1M |
| Total current assets | $67.0M | $44.1M | $26.9M | $26.7M | $22.4M |
| Total assets | $70.6M | $44.9M | $26.9M | $26.9M | $22.4M |
| Accounts payable | $4.63M | $3.24M | $3.78M | $2.39M | $777.0K |
| Total current liabilities | $10.5M | $6.92M | $7.55M | $4.61M | $1.65M |
| Long-term debt | – | $19.3M | $30.9M | $24.9M | – |
| Total liabilities | $35.1M | $50.8M | $38.5M | $29.5M | $6.64M |
| Shareholders' equity | $35.5M | -$5.87M | -$11.6M | -$2.57M | $15.8M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 24, 2026 | Mar 10, 2025 | Mar 25, 2024 | – | – |
| Operating cash flow | -$12.5M | $27.0M | -$17.1M | -$18.1M | -$14.2M |
| Stock-based compensation | $7.03M | $5.06M | $5.35M | $4.09M | $3.75M |
| Financing cash flow | $22.6M | -$13.6M | $6.64M | $20.7M | $4.98M |
| Net change in cash | $10.2M | $13.4M | -$10.5M | $2.67M | -$9.24M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 15.8% | 10.6% | 25.2% | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 10, 2026 | 35.3M | +25.6% | SEC |
| Aug 11, 2026 | 35.1M | +26.0% | SEC |
| May 12, 2026 | 34.7M | +25.8% | SEC |
| Mar 20, 2026 | 34.5M | +24.9% | SEC |
| Nov 10, 2025 | 28.1M | +2.5% | SEC |
| Aug 11, 2025 | 27.8M | +1.7% | SEC |
| May 9, 2025 | 27.6M | +1.1% | SEC |
| Mar 24, 2025 | 27.6M | +1.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.